Whitehawk Therapeutics Q3 net loss widens on R&D expenses
WHWK•Whitehawk Therapeutics reported a third-quarter net loss of $21.21 million, wider than a year earlier and above the $18.88 million analyst estimate. Research and development expenses rose to $18.1 million from $14.3 million.
1. Quarterly results
Whitehawk Therapeutics’ third-quarter net loss was $21.21 million, compared with an analyst estimate of $18.88 million. Operating expenses were $22.94 million, and operating income and pretax loss also missed analyst estimates.
2. Pipeline and outlook
Research and development expenses increased to $18.1 million from $14.3 million a year earlier as the company advanced all three antibody-drug conjugate programs into clinical development. It initiated a Phase 1 trial for HWK-206 and continued dose escalation in HWK-007 and HWK-016; HWK-206 received FDA Fast Track designation. Initial Phase 1 data for HWK-007 and HWK-016 are expected in the first half of 2027, and initial HWK-206 data are expected by year-end 2027. The company expects its cash position to fund operations into the second half of 2028.
